Yes. After the company was delisted from the Nasdaq, it was developed and split into two listed companies , with WuXi Biotech listed on the Hong Kong stock market and WCMC listed on the A-share market, and in the New Triple Board Hopper Pharmaceuticals is a subsidiary of WuXi Kande.
While the chairman of the board of directors of the company said on May 24 that "when all the dust settles, the company will properly handle future capital opportunities in accordance with the capital market arrangements of the entire WuXi AppTec Group. The company will consider new capital opportunities in due course when conditions are ripe in all aspects.
The company publicly replied to investors that WuXi PharmaTech mainly provides small molecule chemical drug discovery, development, production and supporting testing, clinical trial services, medical device testing and precision medicine R&D and production services.
WCMC mainly provides services related to the discovery, development and production of large molecule biologics. The core business of WuXi Biologics and the main business of WuXi AppTec are not the same or similar business, and each of them operates and develops independently without any competition in the same industry.
Warmin Bio (stock code: 2269.HK), a Hong Kong-listed company, is the world's leading open and integrated biopharmaceutical capability and technology enablement platform. The company provides a full range of end-to-end R&D services to global biopharmaceutical and biotechnology companies, helping anyone, any company, discover, develop and produce biologics from concept to commercial production, accelerating the global biopharmaceutical R&D process, lowering R&D costs and benefiting patients.
As of June 30, 2021, there were 408 integrated projects developed on the WuXi Biologics platform, including 212 in preclinical research, 160 in early clinical (Phase I/II), 32 in late clinical (Phase III) and four in commercial production.
The company's planned biopharmaceutical manufacturing sites in China, Ireland, the United States, Germany and Singapore are expected to have a combined capacity of more than 430,000 liters after 2024, which will strongly ensure that the company will be able to provide its customers with biologics that meet global quality standards through a robust and powerful global supply chain network.
Warmin Bio regards environmental, social and governance (ESG) as an important part of its business development and entrepreneurial spirit, and is committed to becoming a global ESG leader in the biopharmaceutical industry. The company continues to empower its global partners with greener, next-generation biopharmaceutical technologies and energy sources, and has established an ESG Committee, led by its Chief Executive Officer, to fulfill its sustainability commitments while improving operational efficiency.